Open AccessDetection of 1-Benzylpiperazine and 1-(3-Trifluoromethylphenyl)-piperazine in Urine Analysis Specimens Using GC-MS and LC-ESI-MS*
Author(s) -
Shawn P. Vorce,
Justin M. Holler,
Barry Levine,
Marilyn R. Past
Publication year - 2008
Publication title -
journal of analytical toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.161
H-Index - 76
eISSN - 1945-2403
pISSN - 0146-4760
DOI - 10.1093/jat/32.6.444
Subject(s) - designer drug , piperazine , chromatography , chemistry , mass spectrometry , urine , electrospray ionization , gas chromatography–mass spectrometry , ecstasy , methamphetamine , stimulant , pharmacology , medicine , drug , organic chemistry , biochemistry , psychiatry
Designer piperazines, such as 1-benzylpiperazine (BZP) and 1-(3-trifluoromethylphenyl)-piperazine (TFMPP), are widely available and have become popular party drugs throughout the world. Used in many countries as legal alternatives to methamphetamine and ecstasy, these designer piperazines exhibit several of the same stimulant and psychoactive properties of their illicit counterparts. Presented is a case study of seven urine analysis specimens analyzed for designer piperazines. A full scan gas chromatography-mass spectrometry screen detected the presence of BZP and TFMPP in all seven specimens. Confirmation using liquid chromatography-electrospray ionization-mass spectrometry operating in selected ion monitoring mode (SIM) yielded urinary concentrations ranging from 13.0 to 429.1 mg/L and 0.79 to 25.4 mg/L for BZP and TFMPP, respectively.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom